GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (CHIX:HIKl) » Definitions » Total Long-Term Liabilities

Hikma Pharmaceuticals (CHIX:HIKL) Total Long-Term Liabilities : £660 Mil (As of Dec. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Hikma Pharmaceuticals Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Hikma Pharmaceuticals's Total Long-Term Liabilities for the quarter that ended in Dec. 2024 was £660 Mil.

Hikma Pharmaceuticals Total Long-Term Liabilities Historical Data

The historical data trend for Hikma Pharmaceuticals's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikma Pharmaceuticals Total Long-Term Liabilities Chart

Hikma Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 713.50 668.53 1,022.97 894.28 659.69

Hikma Pharmaceuticals Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,022.97 951.98 894.28 917.26 659.69

Hikma Pharmaceuticals Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Hikma Pharmaceuticals Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Hikma Pharmaceuticals's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Hikma Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (CHIX:HIKl) » Definitions » Total Long-Term Liabilities
Comparable Companies
LSE:HCM LSE:INDV LSE:AGY LSE:APH LSE:ANCR LSE:EAH LSE:STX AQSE:ANA LSE:PXS LSE:N4P ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA
Traded in Other Exchanges
HKMPY:USA HKMPF:USA HIK:UK H5P:Germany
Address
1 New Burlington Place, London, GBR, W1S 2HR
Website
https://www.hikma.com
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.

Hikma Pharmaceuticals Headlines

No Headlines